Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study

• Jana Käthe Striefler,
• Hanno Riess,
• Philipp Lohneis,
• Sven Bischoff,
• Annika Kurreck,
• Dominik Paul Modest,
• Marcus Bahra,
• Helmut Oettle,
• Marianne Sinn,
• Henrik Bläker,
• Carsten Denkert,
• Sebastian Stintzing,
• Bruno Valentin Sinn,
• Uwe Pelzer

Affiliations

Jana Käthe Striefler

Department of Hematology, Oncology, and Tumor Immunology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Hanno Riess

Department of Hematology, Oncology, and Tumor Immunology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Philipp Lohneis

Faculty of Medicine and University Hospital Cologne, Institute of Pathology, University of Cologne, Cologne, Germany

Sven Bischoff

Department of Hematology, Oncology, and Tumor Immunology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Annika Kurreck

Department of Hematology, Oncology, and Tumor Immunology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Dominik Paul Modest

Department of Hematology, Oncology, and Tumor Immunology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Marcus Bahra

Department of Surgery, Charité –Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Helmut Oettle

Dayclinic for Oncology and Hematology, Outpatient Department of Medical Oncology, Friedrichshafen, Germany

Marianne Sinn

University Medical Center Hamburg-Eppendorf, Oncology, Hematology and Bone Marrow Transplantation with the Section Pneumology (II Medical Clinic and Polyclinic), Hamburg, Germany

Henrik Bläker

Institute of Pathology, Leipzig University Medicine, Leipzig, Germany

Carsten Denkert

Institute of Pathology, University Clinic of Gießen and Marburg, Marburg, Germany

Sebastian Stintzing

Department of Hematology, Oncology, and Tumor Immunology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Bruno Valentin Sinn

Institute of Pathology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Uwe Pelzer

Department of Hematology, Oncology, and Tumor Immunology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany